Ontology highlight
ABSTRACT:
SUBMITTER: Guilhem A
PROVIDER: S-EPMC5708634 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
Guilhem Alexandre A Fargeton Anne-Emmanuelle AE Simon Anne-Claire AC Duffau Pierre P Harle Jean-Robert JR Lavigne Christian C Carette Marie-France MF Bletry Olivier O Kaminsky Pierre P Leguy Vanessa V Lerolle Nathalie N Roux Dominique D Lambert Marc M Chinet Thierry T Bonnet Delphine D Dupuis-Girod Sophie S Rivière Sophie S
PloS one 20171130 11
<h4>Background</h4>Bevacizumab, an anti-VEGF monoclonal antibody, has recently emerged as a new option for severe forms of hereditary hemorrhagic telangiectasia (HHT). Its utilization in this orphan disease has rapidly spread despite the lack of randomized trials and international guidelines. The objective of this study is to report the main clinical data (baseline characteristics, dose schedule, efficacy, adverse events and deaths) of HHT patients treated by intravenous bevacizumab in France.<h ...[more]